No increased risk of inflammatory bowel disease (IBD) was associated with type-2 diabetes treatment with glucagon-like peptide 1 (GLP-1)-based therapies. Compared with the different glucose-lowering medications, disparities in the established hazard ratios were not significant.
Data on the potential risk of IBD in association with GLP-1-based therapies compared with other glucose-lowering agents is still lacking . Dr Heidi Søgaard Christensen (Aalborg University Hospital, Denmark) presented a study that tried to fill the gap of knowledge by using data from the Danish patient, prescription, and civil registration registries between 2007 and 2018.
The cohort included 177,950 patients who received a new prescription of glucose-lowering medications. The median follow-up was 4.8 years and the median age of the adult patients at the start of the study was 63 years. Dr Søgaard Christensen and colleagues identified 412 cases of incident IBD. Overall, treatment with 1 of the GLP-1-based therapies did not show an increased risk of developing IBD with a statistically non-significant hazard ratio (HR) of 0.96 (95% CI 0.72–1.27) in comparison with other diabetes drugs. Distinguishing between GLP-1 receptor agonists and DPP4-inhibitors also did not reveal significantly different IBD risks: HR 1.30 (95% CI 0.86–1.96) and HR 0.84 (95% CI 0.59–1.19), respectively.
Dr Christensen recapped that, overall, no evidence of a risk of IBD following the use of GLP-1-based therapy was detected. “But, we think that the influence of GLP-1 receptor agonists may need further investigation to completely rule out a negative association,” she concluded.
- Christensen HS. GLP-1 based therapies and risk of Inflammatory Bowel Disease: real world evidence from a nationwide cohort study. DOP57, ECCO 2023, 01–04 March, Copenhagen, Denmark.
« Long-term resection potentially better than anti-TNF treatment in CD Next Article
Checking kidney function is important during the course of IBD »
Table of Contents: ECCO 2023
Letter from the Editor
ECCO 2023 Highlights Podcast
What Is New in Biologic Therapy?
Beneficial effect of early, post-operative vedolizumab on endoscopic recurrence in CD
Long-term data supports the established efficacy and safety of ustekinumab in UC
Anti-TNF withdrawal may be a safe option in stable IBD
Intensified drug therapy leads to better stricture morphology in CD
Small Molecules in IBD: State of the Art
Continued efficacy of long-term ozanimod as UC treatment
Upadacitinib successful in the management of both CD and UC
Solid results for long-term therapy of UC with filgotinib
Paediatric IBD: What You Need To Know
Perinatal period is crucial for the risk of developing CD
Early-life antibiotic exposure: a risk factor for paediatric-onset IBD
Paediatric patients with immune-mediated inflammatory disease harbour a heightened cancer risk
Risk Factors and Complications of IBD
Checking kidney function is important during the course of IBD
Diabetes therapy with GLP-1-based drugs does not elevate the risk of IBD
Surgical Approaches: New Developments
Long-term resection potentially better than anti-TNF treatment in CD
Early, post-operative complications in CD reduced by pre-operative enteral nutrition, irrespective of biologic exposure
Pearls of the Posters
Drop in overall IBD procedures during the pandemic
Proton pump inhibitors associated with worse outcomes in CD
Poor sleep in CD linked to low levels of vitamin D
Novel AI tool assessing mucosal inflammation achieves high correlation with histopathologists